

S5 Table. Risk factors for COVID-19–related mortality in patients with aggressive B-cell lymphoma treated with B-cell depleting agents

	Death (n=10)	Survivor (n=32)	Univariate		Multivariable	
			OR (95% CI)	p-value	aOR (95% CI)	p-value
Age (per 1-year increase)	75 (69-83)	66 (59-74)	1.10 (1.01-1.20)	0.035		
Male sex	8 (80.0)	21 (65.6)	2.10 (0.38-11.62)	0.397		
BMI	20.3 (18.9-22.3)	23.5 (20.2-25.9)	0.84 (0.68-1.04)	0.106		
Vaccination status						
Fully vaccinated	6 (60.0)	27 (84.4)	0.28 (0.06-1.36)	0.113		
Underlying comorbidities						
HTN	5 (50.0)	9 (28.1)	2.56 (0.59-11.00)	0.208		
DM	1 (10.0)	11 (34.4)	0.21 (0.02-1.90)	0.165		
CKD	0	2 (6.3)	-	0.999		
CVD	0	0	-	-		
Chronic lung disease	1 (10.0)	3 (9.4)	1.07 (0.10-11.65)	0.953		
ECOG performance status						
0-1	8 (80.0)	29 (90.6)	1.00			
≥ 2	2 (20.0)	3 (9.4)	2.42 (0.34-17.04)	0.376		
B-cell depleting therapy						
RTX	5 (50.0)	27 (84.4)	1.00			
TCE	5 (50.0)	5 (15.6)	5.40 (1.13-25.81)	0.035	8.97 (1.37-58.73)	0.022
Total duration of TCE or RTX therapy	222 (17-371)	132 (89-159)	1.00 (1.00-1.00)	0.728		
Interval > 1 year from last TCE or RTX to COVID-19 diagnosis	0	9 (28.1)	-	0.999		
Prior lymphoma therapy						
Autologous stem-cell transplant	0	6 (18.8)	-	0.999		
CAR T-cell therapy	0	1 (3.1)	-	> 0.999		
Bendamustine therapy	5 (50.0)	5 (15.6)	5.40 (1.13-25.81)	0.035	8.97 (1.37-58.73)	0.022
Lymphoma status						
Response ^{a)}	6 (60.0)	20 (62.5)	1.00			
Non-response	4 (40.0)	12 (37.5)	1.11 (0.26-4.75)	0.887		
Dominant variant						
Omicron	9 (90.0)	29 (90.6)	1.00			
Delta	1 (10.0)	3 (9.4)	1.07 (0.10-11.65)	0.953		

Values are presented as median (IQR) or number (%). aOR, adjusted odds ratio; BMI, body mass index; CAR, chimeric antigen receptor; CI, confidence interval; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; OR, odds ratio; RTX, rituximab; TCE, T-cell engager. ^{a)}Include complete or partial response to treatment.